Vaccine Vortex: Biotech Giants Target Omicron
BioNTech, Moderna, and Johnson & Johnson’re on a first‑class run‑away mission to tackle the newest, fastest‑moving COVID variant – Omicron. News came on Monday (Nov 29) that these pharma giants are racing to develop shots that hit the variant right where it hurts.
Why the Rush?
- Omicron’s arrival has sparked a global frenzy: countries fear a fast‑moving wave even against fully vaccinated crowds.
- Governments are tightening travel borders and roll‑ing out extra restrictions, bracing for a potential surge.
BioNTech & Pfizer: Flashback to Future
BioNTech SE has already kicked off work on a tailored Omicron vaccine, partnering with Pfizer to speed things up. “We’re coming up with a dose that will make Omicron’s power meaningless,” the company hinted.
Moderna: The Wait‑N‑See Approach
Moderna’s CEO Stéphane Bancel told CNBC that shipping a variant‑specific shot could take a few months. He also noted:
“The real effectiveness of our current shots against Omicron is still a mystery.” He added a promise of clearer answers in about two weeks.
Johnson & Johnson: “Work in Progress”
Johnson & Johnson is simultaneously checking if its current vaccine works against Omicron and chipping away at a new, specialized shot. “We’ve started designing a brand‑new vaccine and will move it into clinical studies quickly if the need pops up,” said Mathai Mammen, the global research head for J&J’s pharma unit.
Expert Insight
A top South African infectious‑disease specialist warned that Omicron spreads faster than earlier variants and can slip past immunity from vaccines or prior infection.
What to Watch
The world’s countdown to more accurate data is on. Stay tuned for updates on how these new shots might reshape the fight against the virus.
